BIIB
BIOGEN INC.
Overview
Biogen discovers, develops, and commercializes medicines for serious neurological and immunological diseases. The company markets treatments for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia, and ALS, along with biosimilars and collaborative Alzheimer's disease therapies.
BIOGEN INC is a Healthcare company operating in Drug Manufacturers - General with a $29.48B market cap.
Most recent reported earnings: Q2 FY2026 (Jul 29, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-04-2913 Q&A exchanges
- Q4 FY2025Earnings2026-02-0621 Q&A exchanges
- Q3 FY2025Earnings2025-10-3012 Q&A exchanges
- Q2 FY2025Earnings2025-07-3111 Q&A exchanges
- Q1 FY2025Earnings2025-05-0115 Q&A exchanges
- Q4 FY2024Earnings2025-02-1214 Q&A exchanges
- Q3 FY2024Earnings2024-10-3010 Q&A exchanges
- Q2 FY2024Earnings2024-08-0111 Q&A exchanges
- Q1 FY2024Earnings2024-06-0519 Q&A exchanges
- Q4 FY2023Earnings2024-02-1314 Q&A exchanges
- Q3 FY2023Earnings2023-11-089 Q&A exchanges
- Q2 FY2023Earnings2023-07-2514 Q&A exchanges
- Q1 FY2023Earnings2023-04-2513 Q&A exchanges
- Q4 FY2022Earnings2023-02-1510 Q&A exchanges
- Q3 FY2022Earnings2022-10-2520 Q&A exchanges
- Q2 FY2022Earnings2022-07-2013 Q&A exchanges
- Q1 FY2022Earnings2022-05-0314 Q&A exchanges
- Q4 FY2021Earnings2022-02-0312 Q&A exchanges
- Q3 FY2021Earnings2021-10-2010 Q&A exchanges
- Q2 FY2021Earnings2021-07-229 Q&A exchanges
- Q1 FY2021Earnings2021-04-2216 Q&A exchanges
History
Earnings history
- Q2 FY20262026-07-29EPS— vs $1.94—Rev— vs ——EODHD
- Q1 FY20262026-05-05EPS$3.57 vs $3.03+17.8%Rev$2.48B vs ——EODHD
- Q4 FY20252026-02-05EPS$1.99 vs $1.61+23.6%Rev$2.28B vs ——EODHD
- Q3 FY20252025-10-28EPS$4.81 vs $3.85+24.9%Rev$2.45B vs ——EODHD
- Q2 FY20252025-07-30EPS$5.47 vs $3.88+41.0%Rev$2.65B vs ——EODHD
- Q1 FY20252025-04-30EPS$3.02 vs $2.95+2.4%Rev$2.43B vs ——EODHD
- Q4 FY20242025-02-11EPS$3.44 vs $3.36+2.4%Rev$2.45B vs ——EODHD
- Q3 FY20242024-10-29EPS$4.08 vs $3.79+7.6%Rev$2.47B vs ——EODHD
- Q2 FY20242024-07-31EPS$5.28 vs $4.03+31.0%Rev$2.46B vs ——EODHD
- Q1 FY20242024-04-23EPS$3.67 vs $3.45+6.4%Rev$2.29B vs ——EODHD
- Q4 FY20232024-02-12EPS$3.30 vs $3.18+3.8%Rev$2.39B vs ——EODHD
- Q3 FY20232023-11-07EPS$4.36 vs $3.97+9.8%Rev$2.53B vs ——EODHD
- Q2 FY20232023-07-24EPS$4.02 vs $3.77+6.6%Rev$2.46B vs ——EODHD
- Q1 FY20232023-04-24EPS$3.40 vs $3.28+3.7%Rev$2.46B vs ——EODHD
- Q4 FY20222023-02-14EPS$4.05 vs $3.48+16.4%Rev$2.54B vs ——EODHD
- Q3 FY20222022-10-24EPS$4.77 vs $4.14+15.2%Rev$2.51B vs ——EODHD
- Q2 FY20222022-07-19EPS$5.25 vs $4.06+29.3%Rev$2.59B vs ——EODHD
- Q1 FY20222022-05-02EPS$4.38 vs $4.380.0%Rev$2.53B vs ——EODHD
- Q4 FY20212022-02-02EPS$3.39 vs $3.38+0.3%Rev$2.73B vs ——EODHD
- Q3 FY20212021-10-19EPS$4.77 vs $4.09+16.6%Rev$2.78B vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-29 | — | $1.94 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $3.57 | $3.03 | +17.8% | $2.48B | — | — | EODHD |
| Q4 FY2025 | 2026-02-05 | $1.99 | $1.61 | +23.6% | $2.28B | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $4.81 | $3.85 | +24.9% | $2.45B | — | — | EODHD |
| Q2 FY2025 | 2025-07-30 | $5.47 | $3.88 | +41.0% | $2.65B | — | — | EODHD |
| Q1 FY2025 | 2025-04-30 | $3.02 | $2.95 | +2.4% | $2.43B | — | — | EODHD |
| Q4 FY2024 | 2025-02-11 | $3.44 | $3.36 | +2.4% | $2.45B | — | — | EODHD |
| Q3 FY2024 | 2024-10-29 | $4.08 | $3.79 | +7.6% | $2.47B | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $5.28 | $4.03 | +31.0% | $2.46B | — | — | EODHD |
| Q1 FY2024 | 2024-04-23 | $3.67 | $3.45 | +6.4% | $2.29B | — | — | EODHD |
| Q4 FY2023 | 2024-02-12 | $3.30 | $3.18 | +3.8% | $2.39B | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $4.36 | $3.97 | +9.8% | $2.53B | — | — | EODHD |
| Q2 FY2023 | 2023-07-24 | $4.02 | $3.77 | +6.6% | $2.46B | — | — | EODHD |
| Q1 FY2023 | 2023-04-24 | $3.40 | $3.28 | +3.7% | $2.46B | — | — | EODHD |
| Q4 FY2022 | 2023-02-14 | $4.05 | $3.48 | +16.4% | $2.54B | — | — | EODHD |
| Q3 FY2022 | 2022-10-24 | $4.77 | $4.14 | +15.2% | $2.51B | — | — | EODHD |
| Q2 FY2022 | 2022-07-19 | $5.25 | $4.06 | +29.3% | $2.59B | — | — | EODHD |
| Q1 FY2022 | 2022-05-02 | $4.38 | $4.38 | 0.0% | $2.53B | — | — | EODHD |
| Q4 FY2021 | 2022-02-02 | $3.39 | $3.38 | +0.3% | $2.73B | — | — | EODHD |
| Q3 FY2021 | 2021-10-19 | $4.77 | $4.09 | +16.6% | $2.78B | — | — | EODHD |
Source: EODHD. BIIB reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks BIIB's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 9/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 3 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.64 | $2.32 | +13.8% | -5.1% | -3.2% |
| Q4 FY2026 | $2.18 | $2.21 | -1.4% | -3.3% | -4.1% |
| Q3 FY2026 | $2.45 | $2.26 | +8.6% | -3.2% | -0.3% |
| Q2 FY2026 | $2.54 | $2.46 | +3.2% | -7.3% | -6.5% |
| Q1 FY2025 | $2.65 | $2.41 | +10.0% | +1.7% | +1.2% |
| Q4 FY2025 | $2.37 | $2.28 | +4.1% | -7.4% | -5.7% |
| Q3 FY2025 | $2.45 | $2.30 | +6.5% | -0.1% | -1.9% |
| Q2 FY2025 | $2.50 | $2.43 | +2.9% | +0.7% | +0.3% |
| Q1 FY2024 | $2.77 | $2.46 | +12.4% | -2.6% | -3.3% |
| Q4 FY2024 | $2.46 | $2.41 | +1.9% | -7.8% | -6.6% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Maintained2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Maintained2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Maintained2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Christopher ViehbacherCEO6 mo14 callsCurrentSample
CEO since 2025 • 1/4 beats (25%) • last guidance cut Q2 FY2026
- Robin KramerCFO4 mo5 callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • last guidance cut Q1 FY2026
- Susan H AlexanderEVP Chief Legal Officer4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last call held guidance Q2 FY2026
- Sean GodboutChief Accounting Officer8 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance raise Q1 FY2026
- Nicole MurphyHead of Pharm Ops and Tech4 mono recorded callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • last guidance raise Q2 FY2026
- Ginger GregoryEVP, Human Resources4 mono recorded callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • guidance suspended Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BIIB.
$ curl https://api.spokenalpha.com/v1/companies/BIIBFAQ
Frequently asked about BIIB
Where can I find BIOGEN INC.'s (BIIB) earnings call transcripts?
Spoken Alpha indexes BIIB's earnings call transcripts at https://spokenalpha.com/companies/BIIB. Each call links to attributed speakers and parsed analyst Q&A. BIOGEN INC.'s own investor relations page is at https://investors.biogen.com/.
When was BIOGEN INC.'s most recent earnings call?
BIOGEN INC. (BIIB) held its most recent earnings call on 2026-04-29, covering fiscal Q1 2026.
What sector is BIIB in?
BIOGEN INC. (BIIB) operates in the Healthcare sector (Drug Manufacturers - General industry).